Clinical presentation of MEN 2A in index vs. non-index patients

[1]  D. Führer-Sakel,et al.  The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative Medicine. , 2023, The Journal of clinical endocrinology and metabolism.

[2]  A. Buchanan,et al.  Thyroidectomy Outcomes in Patients Identified With RET Pathogenic Variants Through a Population Genomic Screening Program. , 2023, JAMA otolaryngology-- head & neck surgery.

[3]  A. Stang,et al.  Temporal trends in referrals of RET gene carriers for neck surgery to a tertiary surgical center in the era of international management guidelines , 2022, Endocrine.

[4]  K. Lorenz,et al.  Genotype‐specific progression of hereditary medullary thyroid cancer , 2018, Human mutation.

[5]  T. Bruckner,et al.  Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon‐specific penetrance and changes in management during the last four decades , 2017, Clinical endocrinology.

[6]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[7]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[8]  Rong Mao,et al.  Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2‐associated RET sequence variation and reference for genotype/phenotype correlations , 2009, Human mutation.

[9]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .